ES2564290T3 - Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento - Google Patents
Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento Download PDFInfo
- Publication number
- ES2564290T3 ES2564290T3 ES11842681.6T ES11842681T ES2564290T3 ES 2564290 T3 ES2564290 T3 ES 2564290T3 ES 11842681 T ES11842681 T ES 11842681T ES 2564290 T3 ES2564290 T3 ES 2564290T3
- Authority
- ES
- Spain
- Prior art keywords
- complement
- ic3b
- lateral flow
- complement activation
- intact
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000024203 complement activation Effects 0.000 title abstract description 44
- 238000003018 immunoassay Methods 0.000 title abstract description 28
- 238000000034 method Methods 0.000 title description 31
- 230000000295 complement effect Effects 0.000 title description 27
- 238000011156 evaluation Methods 0.000 title 1
- 108010078015 Complement C3b Proteins 0.000 abstract description 52
- 238000003556 assay Methods 0.000 abstract description 17
- 239000012528 membrane Substances 0.000 abstract description 17
- 238000001514 detection method Methods 0.000 abstract description 15
- 210000001124 body fluid Anatomy 0.000 abstract description 14
- 239000010839 body fluid Substances 0.000 abstract description 14
- 239000012491 analyte Substances 0.000 abstract description 8
- 108010069112 Complement System Proteins Proteins 0.000 abstract description 4
- 102000000989 Complement System Proteins Human genes 0.000 abstract description 4
- 239000003550 marker Substances 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 36
- 102100022133 Complement C3 Human genes 0.000 description 34
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 34
- 239000000523 sample Substances 0.000 description 33
- 208000014674 injury Diseases 0.000 description 27
- 230000002757 inflammatory effect Effects 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000009429 distress Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 230000006378 damage Effects 0.000 description 13
- 230000008733 trauma Effects 0.000 description 13
- 241000283707 Capra Species 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000004074 complement inhibitor Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 108090000044 Complement Factor I Proteins 0.000 description 2
- 102100035431 Complement factor I Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010052926 complement C3d,g Proteins 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40929710P | 2010-11-02 | 2010-11-02 | |
| US409297P | 2010-11-02 | ||
| PCT/US2011/058945 WO2012071145A1 (en) | 2010-11-02 | 2011-11-02 | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2564290T3 true ES2564290T3 (es) | 2016-03-21 |
Family
ID=46146161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11842681.6T Active ES2564290T3 (es) | 2010-11-02 | 2011-11-02 | Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9182396B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2635702B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5859557B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011332241B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2816423A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2564290T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX340094B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012071145A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5859557B2 (ja) * | 2010-11-02 | 2016-02-10 | カイファ， インコーポレイテッド | 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 |
| US8865164B2 (en) * | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| CN105283761B (zh) * | 2013-06-10 | 2018-02-09 | 旭化成株式会社 | 免疫层析诊断试剂盒 |
| CN106461661A (zh) | 2014-05-02 | 2017-02-22 | Uab研究基金会 | 用于诊断和治疗脑膜炎的方法及组合物 |
| WO2017040243A1 (en) * | 2015-08-28 | 2017-03-09 | Kypha, Inc. | Methods for predicting flare and improving treatment of patients |
| KR102141591B1 (ko) * | 2016-05-13 | 2020-09-14 | 광주과학기술원 | 진단용 키트 |
| EP3775900A1 (en) * | 2018-03-26 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | High throughput method for measuring the protease activity of complement c3 convertase |
| EP3581934A1 (en) * | 2018-06-14 | 2019-12-18 | Otto-von-Guericke-Universität Magdeburg | Complement factors for diagnosis of low-grade infections in a human subject |
| WO2021222169A1 (en) * | 2020-04-27 | 2021-11-04 | Zinselmeyer Bernd H | Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2 |
| WO2022067259A1 (en) * | 2020-09-28 | 2022-03-31 | Allegheny Singer Research Institute | Methods for determining a level of a cell fragment-bound complement activation product |
| US20240302366A1 (en) * | 2021-01-26 | 2024-09-12 | Sekisui Medical Co., Ltd. | Immunological assay method |
| EP4334719A4 (en) * | 2021-05-07 | 2025-04-16 | Kypha, Inc. | TARGET MEASUREMENT |
| WO2023192436A1 (en) * | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| JPS595958B2 (ja) | 1975-12-30 | 1984-02-08 | トウキヨウケイソウ カブシキガイシヤ | 変量測定・伝送装置 |
| DE3366421D1 (en) * | 1982-06-14 | 1986-10-30 | Upjohn Co | Method and kit for removing and assaying complement system fragments |
| SE452067B (sv) | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Reagens for och sett vid immunkemisk bestemning av c3a |
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| IL89790A (en) | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| US7371582B2 (en) * | 2002-01-23 | 2008-05-13 | Boditechmed Inc. | Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor |
| WO2004093636A2 (en) * | 2003-04-17 | 2004-11-04 | Rauno Joks | PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY |
| KR20060015646A (ko) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| US20070224703A1 (en) | 2003-09-29 | 2007-09-27 | Fariba Nayeri | Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids |
| WO2005078442A1 (en) | 2004-02-10 | 2005-08-25 | Dantini Daniel C | Comprehensive food allergy test |
| US20060292700A1 (en) * | 2005-06-22 | 2006-12-28 | Naishu Wang | Diffused interrupted lateral flow immunoassay device and method |
| WO2006124888A2 (en) * | 2005-05-16 | 2006-11-23 | Brendan Bioscience, Llc | Detection of antigen specific immunocomplexes |
| US7910381B2 (en) | 2005-10-13 | 2011-03-22 | BioAssay Works | Immuno gold lateral flow assay |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| EP2313527A4 (en) * | 2008-07-15 | 2012-11-21 | Rapid Pathogen Screening Inc | Lateral flow NUCLEIC DETECTOR |
| WO2010077722A1 (en) * | 2008-12-30 | 2010-07-08 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis |
| WO2010135717A2 (en) * | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| JP5859557B2 (ja) | 2010-11-02 | 2016-02-10 | カイファ， インコーポレイテッド | 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
-
2011
- 2011-11-02 JP JP2013537784A patent/JP5859557B2/ja active Active
- 2011-11-02 EP EP11842681.6A patent/EP2635702B1/en active Active
- 2011-11-02 US US13/287,432 patent/US9182396B2/en active Active
- 2011-11-02 ES ES11842681.6T patent/ES2564290T3/es active Active
- 2011-11-02 EP EP15199549.5A patent/EP3095876A1/en not_active Withdrawn
- 2011-11-02 MX MX2013004960A patent/MX340094B/es active IP Right Grant
- 2011-11-02 WO PCT/US2011/058945 patent/WO2012071145A1/en not_active Ceased
- 2011-11-02 AU AU2011332241A patent/AU2011332241B2/en active Active
- 2011-11-02 CA CA2816423A patent/CA2816423A1/en not_active Abandoned
-
2015
- 2015-08-13 US US14/825,437 patent/US9939446B2/en active Active
-
2016
- 2016-02-05 AU AU2016200772A patent/AU2016200772B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013004960A (es) | 2013-12-16 |
| AU2016200772A1 (en) | 2016-02-25 |
| AU2011332241A1 (en) | 2013-05-23 |
| AU2011332241A2 (en) | 2013-06-13 |
| MX340094B (es) | 2016-06-27 |
| US9939446B2 (en) | 2018-04-10 |
| AU2016200772B2 (en) | 2018-02-01 |
| US20120141457A1 (en) | 2012-06-07 |
| EP3095876A1 (en) | 2016-11-23 |
| JP2014502347A (ja) | 2014-01-30 |
| EP2635702A1 (en) | 2013-09-11 |
| JP5859557B2 (ja) | 2016-02-10 |
| US20150346211A1 (en) | 2015-12-03 |
| EP2635702A4 (en) | 2014-04-02 |
| CA2816423A1 (en) | 2012-05-31 |
| US9182396B2 (en) | 2015-11-10 |
| AU2011332241B2 (en) | 2015-11-26 |
| EP2635702B1 (en) | 2016-02-03 |
| WO2012071145A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564290T3 (es) | Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento | |
| ES2684976T3 (es) | Biomarcadores maternos para diabetes gestacional | |
| ES2755623T3 (es) | Procedimiento de detección de coagulación intravascular diseminada o coagulación intravascular diseminada infecciosa | |
| CN101460852A (zh) | Mrp8/14水平用于鉴别个体处于急性冠状动脉综合症风险中的应用 | |
| Ranjan et al. | Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial | |
| ES2842283T3 (es) | Métodos y composiciones para el diagnóstico y tratamiento de la meningitis | |
| Ledecky et al. | Determination of carcinoembryonic antigen and cancer antigen values with the radioimmunoassay method in healthy females dogs. | |
| ES2711921T3 (es) | Detección de la activación del complemento | |
| Redkin et al. | Testing antithrombin level allows predicting a clinical outcome of sepsis | |
| US20190056412A1 (en) | Methods and compositions for determining fortilin levels | |
| JP6555711B2 (ja) | 非解離性大動脈瘤の疾患活動性の判定方法 | |
| TWI429908B (zh) | 腦外傷神經傷害之體外檢測方法 | |
| RU2609839C1 (ru) | Способ дифференциальной диагностики гиперчувствительности к яду пчелы (apis mellifera) | |
| KR20230092930A (ko) | 담관암종의 표지자로서의 timp1 | |
| Zeynettin et al. | The value of procalsitonin in determining the severity acute pancreatitis cases | |
| El-Garem et al. | Use of the urinary trypsinogen-2 dipstick test in early diagnosis of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) | |
| JP5887082B2 (ja) | 炎症状態の検出方法 | |
| Di Paola et al. | Determination of whether screening tests for chronic atrophic gastritis really has a positive predictive value | |
| HK1234826B (en) | Methods and compositions for diagnosis and treatment of meningitis | |
| HK1234826A1 (en) | Methods and compositions for diagnosis and treatment of meningitis | |
| JP2020505389A (ja) | 子宮内膜症の予後及び治療におけるｃｄ７１受容体の使用 | |
| WO2012152970A1 (es) | Método de diagnóstico del ictus isquémico |